Skip to content

Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status

Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02241330
Enrollment
284
Registered
2014-09-16
Start date
2014-10-31
Completion date
2015-06-30
Last updated
2016-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zinc Deficiency

Keywords

Zinc, deficiency, biofortification, wheat

Brief summary

The objective of this research is to test the efficacy of Zn biofortified wheat in increasing Zn status in Indian school children aged 6-12 y via a 6 month randomized controlled trial.

Interventions

DIETARY_SUPPLEMENTBiofortified wheat

Wheat was grown by foliar Zn application and is therefore biofortified

DIETARY_SUPPLEMENTFortification

Wheat flour is fortified before testmeal preparation

DIETARY_SUPPLEMENTControl

wheat flour is used as control comparator.

Sponsors

HarvestPlus
CollaboratorOTHER
Swiss Federal Institute of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* generally healthy

Exclusion criteria

* unhealthy

Design outcomes

Primary

MeasureTime frameDescription
Change of plasma zinc values from baseline to endpoint and two months post interventionday 0, random between day 0 and 6 month, 6 month and random between 6 months and 2 months post-interventionplasma zinc will be measured at baseline, midpoint (random sparse sampling), endpoint (6 months) and randomly within two months post-intervention

Secondary

MeasureTime frameDescription
Change in the chronic inflammation marker from baseline to 6 months and 2 month post interventionday 0, random during the intervention, month 6, and random 2 months post interventionAGP will be measured at baseline, midpoint (random sparse sampling), endpoint (6 months)and randomly within two months post-intervention
Change in Iron status from baseline to the end of the intervention and 2 months post-interventionday 0, random during the intervention, month 6, and random 2 months post interventionHb will be measured at baseline, midpoint (random sparse sampling), endpoint (6 months) and randomly within two months post-intervention
Change in Iron status from baseline to the end of intervention, and within two months post-interventionday 0, random during the intervention, month 6, and random 2 months post interventionSerum ferritin will be measured at baseline, midpoint (random sparse sampling), endpoint and randomly within two months post-intervention
New Zn biomarkersday 0, random during the intervention, month 6, and random 2 months post interventionnew potential zn biomarkers will be measured in whole blood and plasma at baseline, midpoint (random sparse sampling), endpoint and randomly within two months post-intervention
Change in the Inflammation marker from baseline to the end of the intervention, as well as post-interventionday 0, random during the intervention, month 6, and random 2 months post interventionCRP will be measured at baseline, midpoint (random sparse sampling), endpoint (end of intervention) and randomly within two months post-intervention
Characterization of gut microflorabaseline, endpoint (6 months)Characterization of microflora will be done in a subsamples of children (taken randomly), at baseline and at the end of feeding (6 months)
Anthropometrybaseline (day 0), endpoint (6 months)anthropometry, such as height, weight will be measured at baseline and endpoint of the study
morbiditythroughout the studymorbidity, mainly diarrhea and pneumonia episodes, will be recorded throughout the study
New potential Zn biomarkers in buccal cellsday 0, random during the intervention, month 6, and random 2 months post interventionMT RNA transcript in buccal cells will be measured at baseline, midpoint (random sparse sampling), endpoint

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026